Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $11.38

Shares of Novavax, Inc. (NASDAQ:NVAX) have earned an average recommendation of “Hold” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $11.3750.

Several equities research analysts have recently issued reports on NVAX shares. Wall Street Zen cut shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Novavax in a report on Thursday. HC Wainwright lifted their target price on Novavax from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. B. Riley reissued a “buy” rating and set a $16.00 price target (down from $18.00) on shares of Novavax in a research note on Monday, November 10th. Finally, Bank of America reaffirmed an “underperform” rating and issued a $7.00 price objective (down previously from $9.00) on shares of Novavax in a research note on Wednesday, August 20th.

Institutional Trading of Novavax

A number of large investors have recently made changes to their positions in the business. State of Wyoming purchased a new stake in shares of Novavax during the 2nd quarter valued at about $52,000. Signaturefd LLC boosted its holdings in shares of Novavax by 47.2% in the 2nd quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 3,122 shares during the period. Vise Technologies Inc. bought a new position in shares of Novavax during the 2nd quarter valued at approximately $70,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Novavax during the 1st quarter valued at $71,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Novavax in the second quarter worth $72,000. 53.04% of the stock is currently owned by institutional investors.

Novavax Trading Down 1.3%

Shares of NASDAQ:NVAX opened at $6.97 on Friday. Novavax has a 12-month low of $5.01 and a 12-month high of $11.55. The company has a market cap of $1.13 billion, a PE ratio of 3.06, a price-to-earnings-growth ratio of 0.12 and a beta of 2.68. The stock has a 50 day moving average of $8.34 and a 200 day moving average of $7.59. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). The firm had revenue of $70.45 million during the quarter, compared to the consensus estimate of $55.63 million. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The business’s revenue for the quarter was down 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.76) earnings per share. Novavax has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Novavax will post -1.46 EPS for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.